The use of intranasal sufentanil and/or s‐ketamine for treatment of procedural pain in children in an ambulatory setting: A retrospective observational study

Background Minor but painful medical procedures are often handled at the operating room. If safe and effective treatment options are available many procedures may be performed outside of the operating room. Objective(s) The objective of this study is to assess the adverse events of intranasal s‐keta...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Acta anaesthesiologica Scandinavica 2024-11, Vol.68 (10), p.1359-1368
Hauptverfasser: Nielsen, Bettina N., Henneberg, Steen W., Olsson, Eva Malmros, Lundeberg, Stefan
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1368
container_issue 10
container_start_page 1359
container_title Acta anaesthesiologica Scandinavica
container_volume 68
creator Nielsen, Bettina N.
Henneberg, Steen W.
Olsson, Eva Malmros
Lundeberg, Stefan
description Background Minor but painful medical procedures are often handled at the operating room. If safe and effective treatment options are available many procedures may be performed outside of the operating room. Objective(s) The objective of this study is to assess the adverse events of intranasal s‐ketamine and/or sufentanil alone or as part of a multimodal analgesic regime for medical procedures outside of the operating room. Secondary outcomes included analgesic effect, doses and indications for use. Design Retrospective observational study. Setting Tertiary care paediatric hospital. Patients Children 1 year up till 18 years. Intervention(s) Intranasal (IN) sufentanil (S), intranasal s‐ketamine (K) or the free combination of the two drugs (SK). Main Outcome Measure(s) The frequency of adverse events including serious adverse events reported by intervention. Results Between 2004 and 2014, 2185 medical procedures were registered, including 652 procedures with IN SK, 1469 procedures with IN S and 64 procedures with IN K. The children's median age was 5.6 years (range 1.0–17.9). Medical procedures with at least one adverse event were 18% with IN SK, 25% with IN K and 18% with IN S. Common adverse events included episodes of vomiting (9%), nausea (8%) and dizziness (3%). In two patients receiving IN S, serious adverse events occurred. One patient had respiratory depression and bronchospasm and another patient with cerebral palsy had a seizure. Both were handled immediately and did not result in any sequelae. The median doses of intranasal sufentanil were 38% lower when combined with s‐ketamine (IN SK free combination: sufentanil dose 0.5 μg/kg (range 0.2–1.3) and s‐ketamine dose 0.5 mg/kg (range 0.2–1.5). IN S monotherapy, sufentanil dose 0.8 μg/kg (range 0.2–2.7)). Similar analgesic effect was reported for S and SK. Conclusions Intranasal sufentanil and/or s‐ketamine are feasible for the treatment of procedural pain in an ambulatory setting with appropriate per‐ and post‐procedural observations and trained staff.
doi_str_mv 10.1111/aas.14510
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3094472522</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3120167776</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2780-ea21391d8b236abef951cf79a6ee1d2fb5bafd322ddc34cb4a4fdbf3a6bb26f73</originalsourceid><addsrcrecordid>eNp1kcuKFDEYhYMoTju68AUk4EYXNZ1LVaXLXTN4gwEXjuviT_LHyViVanMZ6Z2P4Bv4bj6J6enRhWAI5ML3H87hEPKUszNe1xognfG24-weWXE5DE3fqf4-WTHGeNNxJU7Io5Su61O2w_CQnMiBd123YSvy8_IKaUlIF0d9yBECJJhoKg5DhuAnCsGul0jTr-8_vmCG2Qekrn7kiJDnSh1Gd3ExaEusozvwoUpRc-UnG_H2DnXPukyQl7inCXP24fMruqURc1zSDk32N9WDThhvIPslHDzkYvePyQMHU8Ind-cp-fTm9eX5u-biw9v359uLxgi1YQ2CqMG53Wghe9Doho4bpwboEbkVTncanJVCWGtka3QLrbPaSei1Fr1T8pS8OOrWJF8LpjzOPhmcJgi4lDRKNrStEp0QFX3-D3q9lFgdV4oLxnulVF-pl0fK1IApoht30c8Q9yNn46G1sbY23rZW2Wd3ikXPaP-Sf2qqwPoIfPMT7v-vNG63H4-SvwEpoKY2</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3120167776</pqid></control><display><type>article</type><title>The use of intranasal sufentanil and/or s‐ketamine for treatment of procedural pain in children in an ambulatory setting: A retrospective observational study</title><source>MEDLINE</source><source>Access via Wiley Online Library</source><creator>Nielsen, Bettina N. ; Henneberg, Steen W. ; Olsson, Eva Malmros ; Lundeberg, Stefan</creator><creatorcontrib>Nielsen, Bettina N. ; Henneberg, Steen W. ; Olsson, Eva Malmros ; Lundeberg, Stefan</creatorcontrib><description>Background Minor but painful medical procedures are often handled at the operating room. If safe and effective treatment options are available many procedures may be performed outside of the operating room. Objective(s) The objective of this study is to assess the adverse events of intranasal s‐ketamine and/or sufentanil alone or as part of a multimodal analgesic regime for medical procedures outside of the operating room. Secondary outcomes included analgesic effect, doses and indications for use. Design Retrospective observational study. Setting Tertiary care paediatric hospital. Patients Children 1 year up till 18 years. Intervention(s) Intranasal (IN) sufentanil (S), intranasal s‐ketamine (K) or the free combination of the two drugs (SK). Main Outcome Measure(s) The frequency of adverse events including serious adverse events reported by intervention. Results Between 2004 and 2014, 2185 medical procedures were registered, including 652 procedures with IN SK, 1469 procedures with IN S and 64 procedures with IN K. The children's median age was 5.6 years (range 1.0–17.9). Medical procedures with at least one adverse event were 18% with IN SK, 25% with IN K and 18% with IN S. Common adverse events included episodes of vomiting (9%), nausea (8%) and dizziness (3%). In two patients receiving IN S, serious adverse events occurred. One patient had respiratory depression and bronchospasm and another patient with cerebral palsy had a seizure. Both were handled immediately and did not result in any sequelae. The median doses of intranasal sufentanil were 38% lower when combined with s‐ketamine (IN SK free combination: sufentanil dose 0.5 μg/kg (range 0.2–1.3) and s‐ketamine dose 0.5 mg/kg (range 0.2–1.5). IN S monotherapy, sufentanil dose 0.8 μg/kg (range 0.2–2.7)). Similar analgesic effect was reported for S and SK. Conclusions Intranasal sufentanil and/or s‐ketamine are feasible for the treatment of procedural pain in an ambulatory setting with appropriate per‐ and post‐procedural observations and trained staff.</description><identifier>ISSN: 0001-5172</identifier><identifier>ISSN: 1399-6576</identifier><identifier>EISSN: 1399-6576</identifier><identifier>DOI: 10.1111/aas.14510</identifier><identifier>PMID: 39155580</identifier><language>eng</language><publisher>England: Wiley Subscription Services, Inc</publisher><subject>acute pain ; Administration, Intranasal ; Adolescent ; Adverse events ; Ambulatory Care ; Analgesics ; Analgesics - administration &amp; dosage ; Analgesics - therapeutic use ; Bronchospasm ; Child ; Child, Preschool ; Children ; Complications ; Developmental disabilities ; Female ; Humans ; Infant ; intranasal ; Ketamine ; Ketamine - administration &amp; dosage ; Ketamine - adverse effects ; Ketamine - therapeutic use ; Male ; Medical procedures ; Observational studies ; Pain ; Pain, Procedural - etiology ; Pain, Procedural - prevention &amp; control ; Patients ; Pediatrics ; Retrospective Studies ; Seizures ; Sufentanil ; Sufentanil - administration &amp; dosage ; Sufentanil - adverse effects ; s‐ketamine</subject><ispartof>Acta anaesthesiologica Scandinavica, 2024-11, Vol.68 (10), p.1359-1368</ispartof><rights>2024 The Author(s). published by John Wiley &amp; Sons Ltd on behalf of Acta Anaesthesiologica Scandinavica Foundation.</rights><rights>2024 The Author(s). Acta Anaesthesiologica Scandinavica published by John Wiley &amp; Sons Ltd on behalf of Acta Anaesthesiologica Scandinavica Foundation.</rights><rights>2024. This article is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c2780-ea21391d8b236abef951cf79a6ee1d2fb5bafd322ddc34cb4a4fdbf3a6bb26f73</cites><orcidid>0000-0003-2273-2942 ; 0000-0001-9893-890X ; 0000-0002-6576-623X ; 0000-0001-7848-4752</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Faas.14510$$EPDF$$P50$$Gwiley$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Faas.14510$$EHTML$$P50$$Gwiley$$Hfree_for_read</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39155580$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Nielsen, Bettina N.</creatorcontrib><creatorcontrib>Henneberg, Steen W.</creatorcontrib><creatorcontrib>Olsson, Eva Malmros</creatorcontrib><creatorcontrib>Lundeberg, Stefan</creatorcontrib><title>The use of intranasal sufentanil and/or s‐ketamine for treatment of procedural pain in children in an ambulatory setting: A retrospective observational study</title><title>Acta anaesthesiologica Scandinavica</title><addtitle>Acta Anaesthesiol Scand</addtitle><description>Background Minor but painful medical procedures are often handled at the operating room. If safe and effective treatment options are available many procedures may be performed outside of the operating room. Objective(s) The objective of this study is to assess the adverse events of intranasal s‐ketamine and/or sufentanil alone or as part of a multimodal analgesic regime for medical procedures outside of the operating room. Secondary outcomes included analgesic effect, doses and indications for use. Design Retrospective observational study. Setting Tertiary care paediatric hospital. Patients Children 1 year up till 18 years. Intervention(s) Intranasal (IN) sufentanil (S), intranasal s‐ketamine (K) or the free combination of the two drugs (SK). Main Outcome Measure(s) The frequency of adverse events including serious adverse events reported by intervention. Results Between 2004 and 2014, 2185 medical procedures were registered, including 652 procedures with IN SK, 1469 procedures with IN S and 64 procedures with IN K. The children's median age was 5.6 years (range 1.0–17.9). Medical procedures with at least one adverse event were 18% with IN SK, 25% with IN K and 18% with IN S. Common adverse events included episodes of vomiting (9%), nausea (8%) and dizziness (3%). In two patients receiving IN S, serious adverse events occurred. One patient had respiratory depression and bronchospasm and another patient with cerebral palsy had a seizure. Both were handled immediately and did not result in any sequelae. The median doses of intranasal sufentanil were 38% lower when combined with s‐ketamine (IN SK free combination: sufentanil dose 0.5 μg/kg (range 0.2–1.3) and s‐ketamine dose 0.5 mg/kg (range 0.2–1.5). IN S monotherapy, sufentanil dose 0.8 μg/kg (range 0.2–2.7)). Similar analgesic effect was reported for S and SK. Conclusions Intranasal sufentanil and/or s‐ketamine are feasible for the treatment of procedural pain in an ambulatory setting with appropriate per‐ and post‐procedural observations and trained staff.</description><subject>acute pain</subject><subject>Administration, Intranasal</subject><subject>Adolescent</subject><subject>Adverse events</subject><subject>Ambulatory Care</subject><subject>Analgesics</subject><subject>Analgesics - administration &amp; dosage</subject><subject>Analgesics - therapeutic use</subject><subject>Bronchospasm</subject><subject>Child</subject><subject>Child, Preschool</subject><subject>Children</subject><subject>Complications</subject><subject>Developmental disabilities</subject><subject>Female</subject><subject>Humans</subject><subject>Infant</subject><subject>intranasal</subject><subject>Ketamine</subject><subject>Ketamine - administration &amp; dosage</subject><subject>Ketamine - adverse effects</subject><subject>Ketamine - therapeutic use</subject><subject>Male</subject><subject>Medical procedures</subject><subject>Observational studies</subject><subject>Pain</subject><subject>Pain, Procedural - etiology</subject><subject>Pain, Procedural - prevention &amp; control</subject><subject>Patients</subject><subject>Pediatrics</subject><subject>Retrospective Studies</subject><subject>Seizures</subject><subject>Sufentanil</subject><subject>Sufentanil - administration &amp; dosage</subject><subject>Sufentanil - adverse effects</subject><subject>s‐ketamine</subject><issn>0001-5172</issn><issn>1399-6576</issn><issn>1399-6576</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>WIN</sourceid><sourceid>EIF</sourceid><recordid>eNp1kcuKFDEYhYMoTju68AUk4EYXNZ1LVaXLXTN4gwEXjuviT_LHyViVanMZ6Z2P4Bv4bj6J6enRhWAI5ML3H87hEPKUszNe1xognfG24-weWXE5DE3fqf4-WTHGeNNxJU7Io5Su61O2w_CQnMiBd123YSvy8_IKaUlIF0d9yBECJJhoKg5DhuAnCsGul0jTr-8_vmCG2Qekrn7kiJDnSh1Gd3ExaEusozvwoUpRc-UnG_H2DnXPukyQl7inCXP24fMruqURc1zSDk32N9WDThhvIPslHDzkYvePyQMHU8Ind-cp-fTm9eX5u-biw9v359uLxgi1YQ2CqMG53Wghe9Doho4bpwboEbkVTncanJVCWGtka3QLrbPaSei1Fr1T8pS8OOrWJF8LpjzOPhmcJgi4lDRKNrStEp0QFX3-D3q9lFgdV4oLxnulVF-pl0fK1IApoht30c8Q9yNn46G1sbY23rZW2Wd3ikXPaP-Sf2qqwPoIfPMT7v-vNG63H4-SvwEpoKY2</recordid><startdate>202411</startdate><enddate>202411</enddate><creator>Nielsen, Bettina N.</creator><creator>Henneberg, Steen W.</creator><creator>Olsson, Eva Malmros</creator><creator>Lundeberg, Stefan</creator><general>Wiley Subscription Services, Inc</general><scope>24P</scope><scope>WIN</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7TK</scope><scope>H94</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-2273-2942</orcidid><orcidid>https://orcid.org/0000-0001-9893-890X</orcidid><orcidid>https://orcid.org/0000-0002-6576-623X</orcidid><orcidid>https://orcid.org/0000-0001-7848-4752</orcidid></search><sort><creationdate>202411</creationdate><title>The use of intranasal sufentanil and/or s‐ketamine for treatment of procedural pain in children in an ambulatory setting: A retrospective observational study</title><author>Nielsen, Bettina N. ; Henneberg, Steen W. ; Olsson, Eva Malmros ; Lundeberg, Stefan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2780-ea21391d8b236abef951cf79a6ee1d2fb5bafd322ddc34cb4a4fdbf3a6bb26f73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>acute pain</topic><topic>Administration, Intranasal</topic><topic>Adolescent</topic><topic>Adverse events</topic><topic>Ambulatory Care</topic><topic>Analgesics</topic><topic>Analgesics - administration &amp; dosage</topic><topic>Analgesics - therapeutic use</topic><topic>Bronchospasm</topic><topic>Child</topic><topic>Child, Preschool</topic><topic>Children</topic><topic>Complications</topic><topic>Developmental disabilities</topic><topic>Female</topic><topic>Humans</topic><topic>Infant</topic><topic>intranasal</topic><topic>Ketamine</topic><topic>Ketamine - administration &amp; dosage</topic><topic>Ketamine - adverse effects</topic><topic>Ketamine - therapeutic use</topic><topic>Male</topic><topic>Medical procedures</topic><topic>Observational studies</topic><topic>Pain</topic><topic>Pain, Procedural - etiology</topic><topic>Pain, Procedural - prevention &amp; control</topic><topic>Patients</topic><topic>Pediatrics</topic><topic>Retrospective Studies</topic><topic>Seizures</topic><topic>Sufentanil</topic><topic>Sufentanil - administration &amp; dosage</topic><topic>Sufentanil - adverse effects</topic><topic>s‐ketamine</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Nielsen, Bettina N.</creatorcontrib><creatorcontrib>Henneberg, Steen W.</creatorcontrib><creatorcontrib>Olsson, Eva Malmros</creatorcontrib><creatorcontrib>Lundeberg, Stefan</creatorcontrib><collection>Wiley Online Library Open Access</collection><collection>Wiley Online Library (Open Access Collection)</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Acta anaesthesiologica Scandinavica</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Nielsen, Bettina N.</au><au>Henneberg, Steen W.</au><au>Olsson, Eva Malmros</au><au>Lundeberg, Stefan</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The use of intranasal sufentanil and/or s‐ketamine for treatment of procedural pain in children in an ambulatory setting: A retrospective observational study</atitle><jtitle>Acta anaesthesiologica Scandinavica</jtitle><addtitle>Acta Anaesthesiol Scand</addtitle><date>2024-11</date><risdate>2024</risdate><volume>68</volume><issue>10</issue><spage>1359</spage><epage>1368</epage><pages>1359-1368</pages><issn>0001-5172</issn><issn>1399-6576</issn><eissn>1399-6576</eissn><abstract>Background Minor but painful medical procedures are often handled at the operating room. If safe and effective treatment options are available many procedures may be performed outside of the operating room. Objective(s) The objective of this study is to assess the adverse events of intranasal s‐ketamine and/or sufentanil alone or as part of a multimodal analgesic regime for medical procedures outside of the operating room. Secondary outcomes included analgesic effect, doses and indications for use. Design Retrospective observational study. Setting Tertiary care paediatric hospital. Patients Children 1 year up till 18 years. Intervention(s) Intranasal (IN) sufentanil (S), intranasal s‐ketamine (K) or the free combination of the two drugs (SK). Main Outcome Measure(s) The frequency of adverse events including serious adverse events reported by intervention. Results Between 2004 and 2014, 2185 medical procedures were registered, including 652 procedures with IN SK, 1469 procedures with IN S and 64 procedures with IN K. The children's median age was 5.6 years (range 1.0–17.9). Medical procedures with at least one adverse event were 18% with IN SK, 25% with IN K and 18% with IN S. Common adverse events included episodes of vomiting (9%), nausea (8%) and dizziness (3%). In two patients receiving IN S, serious adverse events occurred. One patient had respiratory depression and bronchospasm and another patient with cerebral palsy had a seizure. Both were handled immediately and did not result in any sequelae. The median doses of intranasal sufentanil were 38% lower when combined with s‐ketamine (IN SK free combination: sufentanil dose 0.5 μg/kg (range 0.2–1.3) and s‐ketamine dose 0.5 mg/kg (range 0.2–1.5). IN S monotherapy, sufentanil dose 0.8 μg/kg (range 0.2–2.7)). Similar analgesic effect was reported for S and SK. Conclusions Intranasal sufentanil and/or s‐ketamine are feasible for the treatment of procedural pain in an ambulatory setting with appropriate per‐ and post‐procedural observations and trained staff.</abstract><cop>England</cop><pub>Wiley Subscription Services, Inc</pub><pmid>39155580</pmid><doi>10.1111/aas.14510</doi><tpages>10</tpages><orcidid>https://orcid.org/0000-0003-2273-2942</orcidid><orcidid>https://orcid.org/0000-0001-9893-890X</orcidid><orcidid>https://orcid.org/0000-0002-6576-623X</orcidid><orcidid>https://orcid.org/0000-0001-7848-4752</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0001-5172
ispartof Acta anaesthesiologica Scandinavica, 2024-11, Vol.68 (10), p.1359-1368
issn 0001-5172
1399-6576
1399-6576
language eng
recordid cdi_proquest_miscellaneous_3094472522
source MEDLINE; Access via Wiley Online Library
subjects acute pain
Administration, Intranasal
Adolescent
Adverse events
Ambulatory Care
Analgesics
Analgesics - administration & dosage
Analgesics - therapeutic use
Bronchospasm
Child
Child, Preschool
Children
Complications
Developmental disabilities
Female
Humans
Infant
intranasal
Ketamine
Ketamine - administration & dosage
Ketamine - adverse effects
Ketamine - therapeutic use
Male
Medical procedures
Observational studies
Pain
Pain, Procedural - etiology
Pain, Procedural - prevention & control
Patients
Pediatrics
Retrospective Studies
Seizures
Sufentanil
Sufentanil - administration & dosage
Sufentanil - adverse effects
s‐ketamine
title The use of intranasal sufentanil and/or s‐ketamine for treatment of procedural pain in children in an ambulatory setting: A retrospective observational study
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T21%3A57%3A39IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20use%20of%20intranasal%20sufentanil%20and/or%20s%E2%80%90ketamine%20for%20treatment%20of%20procedural%20pain%20in%20children%20in%20an%20ambulatory%20setting:%20A%20retrospective%20observational%20study&rft.jtitle=Acta%20anaesthesiologica%20Scandinavica&rft.au=Nielsen,%20Bettina%20N.&rft.date=2024-11&rft.volume=68&rft.issue=10&rft.spage=1359&rft.epage=1368&rft.pages=1359-1368&rft.issn=0001-5172&rft.eissn=1399-6576&rft_id=info:doi/10.1111/aas.14510&rft_dat=%3Cproquest_cross%3E3120167776%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3120167776&rft_id=info:pmid/39155580&rfr_iscdi=true